Literature DB >> 9713878

Multiple myeloma and renal failure: one center's experience.

C Magee1, J P Vella, W P Tormey, J J Walshe.   

Abstract

Renal involvement remains a major complication of multiple myeloma, particularly in advanced disease. A retrospective analysis was performed of the modes of presentation, treatment and outcome of all patients with multiple myeloma treated in our renal unit between 1987 and 1996. Thirty-four patients were identified: in 26 (76%) the diagnosis of myeloma was made only after referral. Light chains were the most common paraprotein in both serum and urine. Twenty-one (62%) patients underwent renal biopsy: myeloma cast nephropathy was the predominant histological finding in 16 cases. Thirty-one (91%) patients had severe renal failure (GFR < 20 mL/min), with 28 (82%) requiring dialysis within 2 weeks of admission. Despite treatment of presumed precipitaing causes of acute deterioration in renal function, only 1 of these 28 patients subsequently became independent of dialysis. Most had advanced stage myeloma: 29 (85%) were Durie-Salmon stage II or III. Hypercalcemia, sepsis and pathological fractures were the principal complications. Median survival overall was 5 months. The main causes of death were withdrawal of renal replacement therapy (overwhelming myeloma, severe debilitation) and sepsis. Nineteen (56%) patients received long-term (> 1 month) renal replacement therapy with a median survival of 8 months. However, five of these (26%) have survived for more than 12 months on dialysis and report a good quality of life.

Entities:  

Mesh:

Year:  1998        PMID: 9713878     DOI: 10.3109/08860229809045152

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  4 in total

Review 1.  Myeloma light chain cast nephropathy, a review.

Authors:  Insara Jaffer Sathick; Maria Eleni Drosou; Nelson Leung
Journal:  J Nephrol       Date:  2018-05-05       Impact factor: 3.902

Review 2.  Novel approaches for reducing free light chains in patients with myeloma kidney.

Authors:  Colin A Hutchison; Joan Bladé; Paul Cockwell; Mark Cook; Mark Drayson; Jean-Paul Fermand; Efstathios Kastritis; Robert Kyle; Nelson Leung; Sonia Pasquali; Christopher Winearls
Journal:  Nat Rev Nephrol       Date:  2012-02-21       Impact factor: 28.314

3.  Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis.

Authors:  Colin A Hutchison; Arthur R Bradwell; Mark Cook; Kolitha Basnayake; Supratik Basu; Stephen Harding; John Hattersley; Neil D Evans; Mike J Chappel; Paul Sampson; Lukas Foggensteiner; Dwomoa Adu; Paul Cockwell
Journal:  Clin J Am Soc Nephrol       Date:  2009-04-01       Impact factor: 8.237

4.  Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure.

Authors:  Colin A Hutchison; Tim Plant; Mark Drayson; Paul Cockwell; Melpomeni Kountouri; Kolitha Basnayake; Stephen Harding; Arthur R Bradwell; Graham Mead
Journal:  BMC Nephrol       Date:  2008-09-22       Impact factor: 2.388

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.